Triple-Negative Breast Cancer: Next-Generation Sequencing for Target Identification

Am J Pathol. 2017 Oct;187(10):2133-2138. doi: 10.1016/j.ajpath.2017.05.018. Epub 2017 Jul 20.


Presently, the ability to study disease at the most fundamental molecular level has led to a reclassification of human cancers into numerous subtypes that vary in disease progression and response to therapy. Similar to most solid tumors, breast cancer is a heterogeneous disease with considerable variation in histologic and biological features. Triple-negative breast cancer (TNBC) is a subtype of breast cancer in which the estrogen receptor and progesterone receptor are not expressed, and human epidermal growth factor-receptor 2 is not amplified or overexpressed. Data derived from highly complex molecular technologies, such as microarrays and next-generation sequencing, have identified gene expression and somatic mutation profile subsets of TNBC that reflect biological behavior more accurately and may lead to further effective therapeutic targets, better prognosis, and improved outcomes. Herein, we review the genomic findings of TNBC and discuss current efforts in precision medicine as they relate to TNBC.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • DNA Mutational Analysis
  • Female
  • High-Throughput Nucleotide Sequencing / methods*
  • Humans
  • Triple Negative Breast Neoplasms / classification
  • Triple Negative Breast Neoplasms / genetics*
  • Triple Negative Breast Neoplasms / pathology
  • Triple Negative Breast Neoplasms / therapy